These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25009161)

  • 1. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
    Kinon BJ; Kollack-Walker S; Jeste D; Gupta S; Chen L; Case M; Chen J; Stauffer V
    J Geriatr Psychiatry Neurol; 2015 Mar; 28(1):67-79. PubMed ID: 25009161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
    Novick D; Haro JM; Bertsch J; Haddad PM
    J Clin Psychopharmacol; 2010 Oct; 30(5):531-40. PubMed ID: 20814320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
    Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
    J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
    Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
    Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.
    Liu-Seifert H; Ascher-Svanum H; Osuntokun O; Jen KY; Gomez JC
    BMC Psychiatry; 2011 May; 11():87. PubMed ID: 21586165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.
    Wang HH; Cai M; Wang HN; Chen YC; Zhang RG; Wang Y; McAlonan GM; Bai YH; Wu WJ; Guo L; Zhang YH; Tan QR; Zhang ZJ
    J Psychiatr Res; 2017 Feb; 85():59-65. PubMed ID: 27837658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
    Caroff SN; Davis VG; Miller DD; Davis SM; Rosenheck RA; McEvoy JP; Campbell EC; Saltz BL; Riggio S; Chakos MH; Swartz MS; Keefe RS; Stroup TS; Lieberman JA;
    J Clin Psychiatry; 2011 Mar; 72(3):295-303. PubMed ID: 20816031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
    Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
    J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.
    Blumberger DM; Mulsant BH; Kanellopoulos D; Whyte EM; Rothschild AJ; Flint AJ; Meyers BS
    J Clin Psychopharmacol; 2013 Jun; 33(3):391-7. PubMed ID: 23609383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
    Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.
    Woerner MG; Correll CU; Alvir JM; Greenwald B; Delman H; Kane JM
    Neuropsychopharmacology; 2011 Jul; 36(8):1738-46. PubMed ID: 21508932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.